Outlier: Takeda Scores Chinese Clinical Trial Authorization For Diabetes Agent In Record 7 Months
This article was originally published in PharmAsia News
Executive Summary
It’s not an anticancer therapy, and it has only Phase II data from overseas, but Takeda has managed to cut the average clinical trial authorization time for Class 1 new drugs in China by two months.